Dror Bashan - Apr 1, 2023 Form 4 Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Role: PRESIDENT AND CEO, Director
Signature: /s/ Dror Bashan
Stock symbol: PLX
Transactions as of: Apr 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 4/3/2024, 05:30 PM
Previous filing: Sep 9, 2022
Next filing: Aug 17, 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PLX	Common Stock	Award		+264K	+14%		2.15M	Apr 1, 2024	By Trust	F1, F2
holding	PLX	Common Stock						133K	Apr 1, 2023	Direct

Showing 1 to 2 of 2 entries

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents fully-vested restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan").
F2	To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.